Valar Labs
Valar Labs builds software and services for its target customers and markets.
Founded
2021Valar Labs builds software and services for its target customers and markets.
valarlabs.comCrawled Oct 14, 2026
Valar Labs shares news, publications, and resources.
Co-led by DCVC and a16z, this funding will support the advancement of Vesta, world’s first AI test to predict treatment response in bladder cancer, and catalyze expansion in other cancers.
Valar Labs works on solutions for patients and physicians in cancer care.
The company was built around a vision of using AI and pathology slides to help physicians and people with cancer make better decisions.
The page provides a form for contacting Valar Labs, after which a team member will respond.
Valar Labs makes diagnostics that use AI to interpret solid tumors and deliver insights, so physicians and patients can make informed treatment decisions
Valar Labs announces a $22 million Series A co-led by DCVC and a16z. The company says the financing will accelerate the next generation of precision oncology.
Jan 2024 · Valar LabsNews article
Valar Labs announces a $22 million Series A to accelerate AI in precision oncology. Co-led by DCVC and a16z, the funding will support the advancement of Vesta.
Jan 2024 · Valar LabsNews article
Valar Labs debuts an AI-powered cancer care prediction tool and announces a $22 million Series A. The round is co-led by DCVC and a16z Bio + Health; the announcement provides no further details about the tool or its use.
Jan 2024 · LinkedIn · Valar LabsNews article
Valar Labs, a Palo Alto-based company, raises $4 million in seed funding. The company aims to use artificial intelligence to innovate the cancer treatment decision process.
Jan 2024 · citybizNews article